{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:43:42Z","timestamp":1793119422743,"version":"4.5.0"},"reference-count":13,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2018,11,1]]},"DOI":"10.1001\/jamaoncol.2018.1888","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T16:31:05Z","timestamp":1529598665000},"page":"1583","source":"Crossref","is-referenced-by-count":115,"title":["Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck"],"prefix":"10.1001","volume":"4","author":[{"given":"Robert L.","family":"Ferris","sequence":"first","affiliation":[{"name":"University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil F.","family":"Saba","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J.","family":"Gitlitz","sequence":"additional","affiliation":[{"name":"Keck School of Medicine, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Haddad","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar","family":"Sukari","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Neupane","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center, Kansas City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Morris","sequence":"additional","affiliation":[{"name":"University of Cincinnati Cancer Institute, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Misiukiewicz","sequence":"additional","affiliation":[{"name":"Mount Sinai Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie E.","family":"Bauman","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon","family":"Fenton","sequence":"additional","affiliation":[{"name":"West Cancer Center, University of Tennessee, Memphis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Jimeno","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"Adkins","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J.","family":"Schneider","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assuntina G.","family":"Sacco","sequence":"additional","affiliation":[{"name":"VentiRx Pharmaceuticals, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Shirai","sequence":"additional","affiliation":[{"name":"Hollings Cancer Center, Charleston, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Bowles","sequence":"additional","affiliation":[{"name":"Denver Veterans Affairs Medical Center, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gibson","sequence":"additional","affiliation":[{"name":"University Hospitals Seidman Cancer Center, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobenna","family":"Nwizu","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Gottardo","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi L.","family":"Manjarrez","sequence":"additional","affiliation":[{"name":"VentiRx Pharmaceuticals, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory N.","family":"Dietsch","sequence":"additional","affiliation":[{"name":"VentiRx Pharmaceuticals, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Kyle","family":"Bryan","sequence":"additional","affiliation":[{"name":"VentiRx Pharmaceuticals, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Hershberg","sequence":"additional","affiliation":[{"name":"VentiRx Pharmaceuticals, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezra E. W.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"cbr180008r1","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1586\/era.09.113","article-title":"Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.","volume":"9","author":"Rivera","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4-5","key":"cbr180008r2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.oraloncology.2008.05.014","article-title":"Current concepts for the management of head and neck cancer: chemotherapy.","volume":"45","author":"Specenier","year":"2009","journal-title":"Oral Oncol"},{"issue":"29","key":"cbr180008r3","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1200\/JCO.2015.61.1509","article-title":"Immunology and immunotherapy of head and neck cancer.","volume":"33","author":"Ferris","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"cbr180008r4","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s00262-013-1437-3","article-title":"TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.","volume":"62","author":"Stephenson","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"19","key":"cbr180008r5","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck.","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"cbr180008r6","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.1158\/1078-0432.CCR-15-0578","article-title":"Late-stage cancer patients remain highly responsive to immune activation by the selective TLR8 agonist motolimod (VTX-2337).","volume":"21","author":"Dietsch","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"14","key":"cbr180008r7","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1158\/1078-0432.CCR-14-0392","article-title":"A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma.","volume":"20","author":"Northfelt","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"10","key":"cbr180008r8","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1158\/1078-0432.CCR-16-1934","article-title":"Phase 1b trial of the toll-like receptor 8 agonist, motolimod (VTX-2337), combined with cetuximab in patients with recurrent or metastatic SCCHN.","volume":"23","author":"Chow","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"11","key":"cbr180008r9","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer.","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"issue":"23","key":"cbr180008r10","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"4","key":"cbr180008r11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/S1470-2045(15)00560-4","article-title":"Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal Cancer Network for Staging (ICON-S): a multicentre cohort study.","volume":"17","author":"O\u2019Sullivan","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"cbr180008r12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer.","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"cbr180008r13","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1002\/ijc.v136.10","article-title":"Expression of nucleic acid-sensing toll-like receptors predicts HPV16 clearance associated with an E6-directed cell-mediated response.","volume":"136","author":"Scott","year":"2015","journal-title":"Int J Cancer"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2685645","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T16:03:13Z","timestamp":1541692993000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.1888"}},"subtitle":["The Active8 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.1888","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11,1]]}}}